Homology Medicines - FIXX Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FIXX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FIXX, but not buy additional shares or sell existing shares.
View FIXX analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued twelve-month target prices for Homology Medicines' stock. Their FIXX share price forecasts range from $3.10 to $29.00. On average, they anticipate the company's share price to reach $13.01 in the next year. This suggests a possible upside of 371.4% from the stock's current price.
View analysts price targets for FIXX or view top-rated stocks among Wall Street analysts.

Homology Medicines' stock was trading at $3.64 at the start of the year. Since then, FIXX shares have decreased by 24.2% and is now trading at $2.76.
View the best growth stocks for 2022 here.

Homology Medicines, Inc. (NASDAQ:FIXX) announced its quarterly earnings data on Monday, May, 16th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.05. The firm had revenue of $0.80 million for the quarter, compared to analysts' expectations of $1.30 million. Homology Medicines had a negative net margin of 47.29% and a negative trailing twelve-month return on equity of 49.48%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO).

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Homology Medicines' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (1.25%), JPMorgan Chase & Co. (1.24%), Group One Trading L.P. (0.00%), Renaissance Technologies LLC (0.43%), Connor Clark & Lunn Investment Management Ltd. (0.40%) and UBS Group AG (0.33%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Timothy P Kelly, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends.

Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FIXX stock can currently be purchased for approximately $2.76.

Homology Medicines (NASDAQ:FIXX) has a market capitalization of $158.40 million and generates $33.97 million in revenue each year. The company earns $-95,760,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.

The company employs 224 workers across the globe.

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The official website for the company is www.homologymedicines.com. The company can be reached via phone at (781) 301-7277.